ACI
CTMX icon

AMP Capital Investors’s CytomX Therapeutics CTMX Stock Holding History

AMP Capital Investors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-66,353
Closed -$993K – 1168
2018
Q4 		$993K Hold
66,353
– – 0.01% 840
2018
Q3 		$1.21M Sell
66,353
-4,356
-6% -$99.2K 0.01% 846
2018
Q2 		$1.62M Buy
70,709
+4,088
+6% +$104K 0.01% 810
2018
Q1 		$1.87M Hold
66,621
– – 0.01% 773
2017
Q4 		$1.41M Buy
66,621
+26,183
+65% +$543K 0.01% 848
2017
Q3 		$735K Buy
+40,438
New +$631K ﹤0.01% 942

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AMP Capital Investors's CTMX Position: Q1 2019 in Review

AMP Capital Investors sold out of CytomX Therapeutics (CTMX) in Q1 2019, closing a stake of 66,353 shares — an estimated $993K sold.

AMP Capital Investors first reported a position in CTMX in Q3 2017 and held it in 6 quarters. The position peaked at $1.87M in Q1 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q1 2019.

  • AMP Capital Investors reported no remaining CytomX Therapeutics position as of Q1 2019 after selling out during the quarter.
  • AMP Capital Investors sold 66,353 CytomX Therapeutics shares in Q1 2019, an estimated $993K.
  • AMP Capital Investors first reported a position in CytomX Therapeutics in Q3 2017 and held it in 6 quarters.
  • AMP Capital Investors's CytomX Therapeutics position peaked at $1.87M in Q1 2018.
  • 113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2019.

Based on AMP Capital Investors's 13F filing for Q1 2019, filed 15 May 2019.